Get started
Author

D.H. Owen

MA15.09 LCMC3: Long-Term Disease-Free and Overall Survival and their Association with ctDNA after Neoadjuvant Atezolizumab for NSCLC
2024 · D.H. Owen, J.E. Chaft, et al. · Journal of Thoracic Oncology · 7
PDF
EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial
2022 · D.H. Owen, G.A. Durm, et al. · Journal of Thoracic Oncology · 2
PDF
OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.
2022 · D.H. Owen, L. Wei, et al. · Journal of Thoracic Oncology · 2
PDF
2761O Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer
2025 · M. Furqan, A. Alahmadi, et al. · Annals of Oncology · 1
EP.12B.10 Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)
2024 · B. To, S. Farid, et al. · Journal of Thoracic Oncology · 1
PDF
P1.17.55 Transforming Prognostication: A 5-Year Follow-Up Study to Unravel Prognostic Predictors Across Age Groups in NSCLC Using Transformer-Based AI
2025 · L. Brunetti, M. Macerelli, et al. · Journal of Thoracic Oncology
PT2.12.01 Osimertinib Combined With Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients With Metastatic EGFR-Mutated NSCLC
2025 · R. Memmott, J. Gheeya, et al. · Journal of Thoracic Oncology
2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial
2025 · Y.A. Yang, A. Mortazavi, et al. · Annals of Oncology
119P: Real-world first-line (1L) treatment characteristics and physician-reported areas of improvement for patients with advanced non-small cell lung cancer (aNSCLC) with PD-L1 expression ≥50% and without actionable genomic alternations (AGA) in Europe (EU), United States (US) and Asia
2025 · M. Sebastian, D.H. Owen, et al. · Journal of Thoracic Oncology
PDF
611P Cost-effectiveness of perioperative ICI therapy with NSCLC in Japan, USA, Brazil
2024 · T. Aranishi, M. Fujioka, et al. · Annals of Oncology
PDF
MA15.07 Preliminary Analysis of Adjuvant Chemotherapy with Atezolizumab in Stage I-III Resected NSCLC and Clearance of ctDNA
2024 · R. Maniar, E. Shum, et al. · Journal of Thoracic Oncology
PDF
EP.12A.04 Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer
2024 · L. Ramagiri, S. Farid, et al. · Journal of Thoracic Oncology
PDF
P1.25-16 Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study
2023 · C. Presley, D.H. Owen, et al. · Journal of Thoracic Oncology
PDF
PP01.25 Incidence and Timing of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor as Monotherapy or in Combination With Chemotherapy
2023 · A. Secor, S. Zhao, et al. · Journal of Thoracic Oncology
PDF
EP16.03-009 Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping
2022 · D.H. Owen, L. Bucheit, et al. · Journal of Thoracic Oncology
EP08.01-098 Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation
2022 · x. Mo, L. Dong, et al. · Journal of Thoracic Oncology
OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing
2022 · F. Oezkan, S. Hilz, et al. · Journal of Thoracic Oncology
PDF
EP08.01-019 Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
2022 · D. Spakowicz, N. Williams, et al. · Journal of Thoracic Oncology
PDF
Works count: 18
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type